Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Ellis

Showing results (31-40 of 285) with videos related to

Pageof 29
Sort By:
Molecular & Cellular Oncology|December 8, 2018
<i>ESR1</i> fusions drive endocrine therapy resistance and metastasis in breast cancerJonathan T Lei, Xuxu Gou, Matthew J Ellis
International Journal of Breast Cancer|February 2, 2012
Molecular basis of triple negative breast cancer and implications for therapyParvin F Peddi, Matthew J Ellis, Cynthia Ma
Breast Disease|July 23, 2011
Molecular profiling of triple negative breast cancerCynthia X Ma, Jingqin Luo, Matthew J Ellis
Nature Reviews. Clinical Oncology|December 7, 2011
Practical implications of gene-expression-based assays for breast oncologistsAleix Prat, Matthew J Ellis, Charles M Perou
Advances in Experimental Medicine and Biology|March 19, 2016
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast CancerCynthia X Ma, Ron Bose, Matthew J Ellis
Surgical Oncology Clinics of North America|July 13, 2010
Neoadjuvant endocrine therapy for breast cancerJane S Chawla, Cynthia X Ma, Matthew J Ellis
Cancer Cell|August 25, 2004
Successful targeting of ErbB2 receptors-is PTEN the key?Robert J Crowder, Donald P Lombardi, Matthew J Ellis
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effectMatthew J Ellis, Eric Rosen, Holly Dressman, et al.
Chinese Clinical Oncology|September 27, 2015
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerVera Jean Suman, Matthew J Ellis, Cynthia X Ma
Steroids|March 23, 2011
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitorsCynthia X Ma, Robert J Crowder, Matthew J Ellis
Pageof 29

Showing results (31-40 of 285) with videos related to

Sort By:
Pageof 29
Molecular & Cellular Oncology|December 8, 2018
<i>ESR1</i> fusions drive endocrine therapy resistance and metastasis in breast cancerJonathan T Lei, Xuxu Gou, Matthew J Ellis
International Journal of Breast Cancer|February 2, 2012
Molecular basis of triple negative breast cancer and implications for therapyParvin F Peddi, Matthew J Ellis, Cynthia Ma
Breast Disease|July 23, 2011
Molecular profiling of triple negative breast cancerCynthia X Ma, Jingqin Luo, Matthew J Ellis
Nature Reviews. Clinical Oncology|December 7, 2011
Practical implications of gene-expression-based assays for breast oncologistsAleix Prat, Matthew J Ellis, Charles M Perou
Advances in Experimental Medicine and Biology|March 19, 2016
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast CancerCynthia X Ma, Ron Bose, Matthew J Ellis
Surgical Oncology Clinics of North America|July 13, 2010
Neoadjuvant endocrine therapy for breast cancerJane S Chawla, Cynthia X Ma, Matthew J Ellis
Cancer Cell|August 25, 2004
Successful targeting of ErbB2 receptors-is PTEN the key?Robert J Crowder, Donald P Lombardi, Matthew J Ellis
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effectMatthew J Ellis, Eric Rosen, Holly Dressman, et al.
Chinese Clinical Oncology|September 27, 2015
The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerVera Jean Suman, Matthew J Ellis, Cynthia X Ma
Steroids|March 23, 2011
Importance of PI3-kinase pathway in response/resistance to aromatase inhibitorsCynthia X Ma, Robert J Crowder, Matthew J Ellis
Pageof 29